RxDoctor Payments DataLook up a doctor →

Michael Kendrick, MD

Interventional Pain Medicine · Birmingham, ALNPI 1225098163

Payments from drug & device makers

$89,713in general payments, 2019–2025

Across 1,125 payments — averaging $79.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$31K
  • Medtronic$22K
  • Boston Scientific$17K
  • Vertos Medical, Inc.$4K
  • MML US, Inc.$3K
  • Spinal Simplicity, LLC$2K
  • plus $12K from 50 others

What the payments were for

  • Consulting fees$2,7503%
  • Speaking & faculty fees$21,28824%
  • Travel & lodging$7,9119%
  • Food & beverage$26,12829%
  • Education$3370%
  • Other$31,30035%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Zimmer Biomet1$31,300
Medtronic(2 entities)104$21,580
Boston Scientific477$16,523
Vertos Medical, Inc.46$3,651
MML US, Inc.47$2,683
Spinal Simplicity, LLC32$2,347
Saluda Medical Americas, Inc.16$2,304
Vertiflex, Inc.7$1,783
Ortho Dermatologics, A Division Of Bausch Health US, LLC10$970
Forte Bio-pharma LLC66$819
Scilex Pharmaceuticals Inc.36$574
Collegium Pharmaceutical, Inc.32$499
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$446
Foundation Fusion Solutions, LLC2$303
AbbVie(2 entities)13$255
Bausch Health US, LLC13$233
Biodelivery Sciences International, Inc.11$212
Assertio Therapeutics, Inc.20$197
Arbor Pharmaceuticals, Inc.11$195
Almatica Pharma LLC9$190
Redhill Biopharma Inc.9$189
AstraZeneca8$163
Amgen(2 entities)11$159
Globus Medical(2 entities)3$133
Hikma Pharmaceuticals USA7$133
Daiichi Sankyo Inc.7$132
MDD US Operations, LLC11$123
IBSA Pharma Inc.7$121
Relievant Medsystems, Inc.1$118
Abbott7$112
SPR Therapeutics, Inc9$105
Lilly USA, LLC7$99
Nevro Corp.4$97
Eisai Inc.5$95
Si-bone, Inc.4$94
Axonics, Inc.2$91
Novartis5$82
Curonix LLC4$80
Azurity Pharmaceuticals, Inc.5$79
GRT US Holding, Inc.5$73
Radius Health, Inc.2$48
Upsher-smith Laboratories LLC2$39
Pacira Pharmaceuticals Incorporated1$36
Pfizer3$36
Merck2$31
Zyla Life Sciences, Inc.2$28
Shionogi Inc2$23
Takeda Pharmaceuticals U.S.A., Inc.1$20
Averitas Pharma Inc.1$17
Trevena, Inc.1$16
Spinesmith Holdings, LLC1$15
Idorsia Pharmaceuticals US Inc1$14
Supernus Pharmaceuticals, Inc.1$13
Neuronetics, Inc.1$12
Pernix Therapeutics Holdings, Inc.1$12
Teva Pharmaceuticals USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,713 in reported general payments places this provider in the 95th percentile of 33 interventional pain medicine providers in Alabama.

See all interventional pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$278,007
Medicare patients
310
Services billed
5,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl141$88,519
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,473$82,699
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,677$70,873
Xtampza ErOxycodone Myristate79$56,892
Nucynta ErTapentadol Hcl40$37,340
Buprenorphine130$32,138
Gabapentin1,747$25,654
BelbucaBuprenorphine Hcl25$22,741
Pregabalin745$20,156
NucyntaTapentadol Hcl24$19,878
LyricaPregabalin20$19,729
LinzessLinaclotide17$16,496
Lidocaine124$14,155
MovantikNaloxegol Oxalate31$13,408
Morphine Sulfate ErMorphine Sulfate261$10,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca, Nucynta$499$136,851168 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl$133$34,304249 claims
PfizerLyrica$36$19,72920 claims
AbbVieLinzess$255$16,49617 claims
Redhill Biopharma Inc.Movantik$189$13,40831 claims
Upsher-smith Laboratories LLCTopiramate$39$46648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 interventional pain medicine providers in Alabama.

Other interventional pain medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →